Mirum Pharmaceuticals has entered a definitive agreement to acquire Bluejay Therapeutics — a deal that, if finalized, would add brelovitug, a phase 3-stage monoclonal antibody for chronic hepatitis ...
・Phase 2 trial showed 66% of patients achieved undetectable hepatitis delta virus RNA with Vir’s tobevibart-elebsiran combo, with no serious safety issues reported. ・Gilead’s rival therapy bulevirtide ...
A certain mutation in the COVID-19 Delta variant causes infected cells to form disruptive chunks in the lungs and leads to ...
- AZURE-1 and AZURE-4 to form the basis of Mirum’s U.S. BLA Submission Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase ...
Hepatitis delta virus (HDV), a bloodborne infection that is transmitted through infected blood or other bodily fluids, was recently designated as a Group 1 carcinogen by the International Agency for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results